{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:48:28Z","timestamp":1773416908543,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005347","name":"AASLD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol Myers-Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Conatus"},{"DOI":"10.13039\/100014923","name":"CymaBay","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014923","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Exalenz"},{"name":"Galectin"},{"name":"Genfit"},{"DOI":"10.13039\/100005564","name":"Gilead","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Intercept"},{"name":"Immuron"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NGMBio"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shire"},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005347","name":"AASLD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jceh.2019.09.001","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T11:33:29Z","timestamp":1568979209000},"page":"114-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment"],"prefix":"10.1016","volume":"10","author":[{"given":"Robert J.","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamta K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Therapondos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell L.","family":"Shiffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onkar","family":"Kshirsagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mae","family":"Thamer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2019.09.001_bib1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jceh.2019.09.001_bib2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.29811","article-title":"Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease","volume":"68","author":"Backus","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2019.09.001_bib3","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","author":"Ioannou","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.09.001_bib4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.cgh.2017.11.023","article-title":"Patient-reported outcomes following treatment of chronic hepatitis C virus infection with sofosbuvir and velpatasvir, with or without voxilaprevir","volume":"16","author":"Younossi","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2019.09.001_bib5","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cgh.2016.01.009","article-title":"Serum biomarkers indicate long-term reduction in liver fibrosis in patients with sustained virological response to treatment for HCV infection","volume":"14","author":"Lu","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2019.09.001_bib6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.22694","article-title":"Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients","volume":"49","author":"George","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2019.09.001_bib7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/liv.13256","article-title":"Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index","volume":"37","author":"Bachofner","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2019.09.001_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/apc.2011.0191","article-title":"Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis","volume":"26","author":"Jain","year":"2012","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.jceh.2019.09.001_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hep.27069","article-title":"Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C","volume":"60","author":"Vergniol","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2019.09.001_bib10","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/ajg.2014.214","article-title":"Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans","volume":"109","author":"El-Serag","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.001_bib11","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1007\/s10620-015-3760-3","article-title":"Concurrent obesity, diabetes, and steatosis increase risk of advanced fibrosis among HCV patients: a systematic review","volume":"60","author":"Dyal","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jceh.2019.09.001_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2019.09.001_bib13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/apt.14241","article-title":"Ethnic disparities in progression to advanced liver disease and overall survival in patients with chronic hepatitis C: impact of a sustained virological response","volume":"46","author":"Le","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2019.09.001_bib14","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41395-018-0033-8","article-title":"Race\/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment","volume":"113","author":"Wong","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.001_bib15","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s10903-016-0350-1","article-title":"Awareness of hepatitis C virus seropositivity and chronic infection in the hispanic community health study\/study of latinos (HCHS\/SOL)","volume":"18","author":"Kuniholm","year":"2016","journal-title":"J\u00a0Immigr Minority Health"},{"key":"10.1016\/j.jceh.2019.09.001_bib16","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/apt.14327","article-title":"Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey","volume":"46","author":"Wong","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2019.09.001_bib17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/oby.20426","article-title":"Racial differences in nonalcoholic fatty liver disease in the U.S. population","volume":"22","author":"Schneider","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jceh.2019.09.001_bib18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis","volume":"16","author":"Rich","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2019.09.001_bib19","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.amjcard.2017.03.010","article-title":"Frequency of nonalcoholic fatty liver disease and subclinical atherosclerosis among young Mexican Americans","volume":"119","author":"Gill","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jceh.2019.09.001_bib20","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2036.2010.04556.x","article-title":"Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"33","author":"Dowman","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2019.09.001_bib21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1053\/j.gastro.2004.12.004","article-title":"Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease","volume":"128","author":"Ioannou","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2019.09.001_bib22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/jhep.2002.30690","article-title":"Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association","volume":"35","author":"Pagano","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2019.09.001_bib23","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.jceh.2019.09.001_bib24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s10620-015-3983-3","article-title":"Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients: a systematic review","volume":"61","author":"Dyal","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jceh.2019.09.001_bib25","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1053\/jhep.2001.24432","article-title":"Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity","volume":"33","author":"Adinolfi","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2019.09.001_bib26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/gut.2004.050302","article-title":"Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C","volume":"54","author":"Fartoux","year":"2005","journal-title":"Gut"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688319302348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688319302348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:05:41Z","timestamp":1760853941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688319302348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0973688319302348"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2019.09.001","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2019.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}